Eradicate Cancer

Does Sugar Cause Cancer? From Dr Abhi Ghose , hematology- oncologist Phoenix , AZ #cancerawareness #cancertreatment #CancerPrevention #cancer #sugar

2018 ASCO: PREOPANC-1 Trial Compares Preoperative Chemoradiotherapy vs Immediate Surgery for Pancreatic Cancer - The ASCO Post A randomized, phase III trial found that patients who received chemoradiotherapy before pancreatic cancer surgery had better disease-free survival than those who started their treatment with surgery, which is the current standard of care. In addition, the 2-year survival rate was higher for those wh...

For a limted time only...
Get a second opinion from Cancer physicians in USA for Rs 2800 ($45) through eradicatecancer.com !

Osimertinib Improves Progression-Free Survival for EGFR -Positive NSCLC in the Phase III FLAURA Trial - The ASCO Post On July 27, it was announced that the phase III FLAURA trial showed a statistically significant and clinically meaningful progression-free survival benefit with osimertinib (Tagrisso) compared to current first-line standard-of-care treatment (erlotinib [Tarceva] or gefitinib [Iressa]) in previously…

New development for Lung Cancer patients with EGFR mutation

Osimertinib Improves Progression-Free Survival for EGFR -Positive NSCLC in the Phase III FLAURA Trial - The ASCO Post On July 27, it was announced that the phase III FLAURA trial showed a statistically significant and clinically meaningful progression-free survival benefit with osimertinib (Tagrisso) compared to current first-line standard-of-care treatment (erlotinib [Tarceva] or gefitinib [Iressa]) in previously…

MammaPrint Test Addressed in ASCO Breast Cancer Guideline Update - The ASCO Post New recommendations on the use of the MammaPrint genomic test issued on July 10 will help guide decisions on adjuvant systemic therapy for women with early breast cancer. The recommendations update the ASCO 2016 clinical practice guideline on the use of biomarkers in these patients.

First-in-Class T-Cell Stimulator Varlilumab in Advanced Solid Tumors - The ASCO Post has shown that the first-in-class agonist anti-CD27 antibody varlilumab is well tolerated and active in patients with advanced solid tumors. CD27 is a co-stimulatory molecule on T cells that induces intracellular signaling for cellular activation, proliferation, effector function, and survival upon…

FDA Approves Ribociclib as Initial Therapy for Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer - The ASCO Post (FDA) approved ribociclib (Kisqali), a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative advance...

Another milestone in the immunotherapeutics. New and safer treatment for newly diagnosed Lung Cancer patients.

FDA Approves Pembrolizumab as First-Line Treatment for PD-L1–Positive Non–Small Cell Lung Cancer - The ASCO Post On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors express programmed cell death ligand 1 (PD-L1) as determined by an FDA-approved test.